These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 15849513)

  • 1. Neuroendocrine hepatic metastases: does aggressive management improve survival?
    Touzios JG; Kiely JM; Pitt SC; Rilling WS; Quebbeman EJ; Wilson SD; Pitt HA
    Ann Surg; 2005 May; 241(5):776-83; discussion 783-5. PubMed ID: 15849513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.
    Gupta S; Yao JC; Ahrar K; Wallace MJ; Morello FA; Madoff DC; Murthy R; Hicks ME; Ajani JA
    Cancer J; 2003; 9(4):261-7. PubMed ID: 12967136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
    Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
    Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic neuroendocrine hepatic tumors: resection improves survival.
    Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
    Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
    Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
    Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma.
    Arrese D; McNally ME; Chokshi R; Feria-Arias E; Schmidt C; Klemanski D; Gregory G; Khabiri H; Shah M; Bloomston M
    Ann Surg Oncol; 2013 Apr; 20(4):1114-20. PubMed ID: 23456380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors.
    Diamandidou E; Ajani JA; Yang DJ; Chuang VP; Brown CA; Carrasco HC; Lawrence DD; Wallace S
    AJR Am J Roentgenol; 1998 Feb; 170(2):339-44. PubMed ID: 9456942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors.
    Clouse ME; Perry L; Stuart K; Stokes KR
    Digestion; 1994; 55 Suppl 3():92-7. PubMed ID: 7698544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors.
    Yao KA; Talamonti MS; Nemcek A; Angelos P; Chrisman H; Skarda J; Benson AB; Rao S; Joehl RJ
    Surgery; 2001 Oct; 130(4):677-82; discussion 682-5. PubMed ID: 11602899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic neuroendocrine tumors: presentation, management, and outcomes.
    Nissen NN; Kim AS; Yu R; Wolin EM; Friedman ML; Lo SK; Wachsman AM; Colquhoun SD
    Am Surg; 2009 Oct; 75(10):1025-9. PubMed ID: 19886158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic surgery for metastases from neuroendocrine tumors.
    Sarmiento JM; Que FG
    Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization.
    Liapi E; Geschwind JF; Vossen JA; Buijs M; Georgiades CS; Bluemke DA; Kamel IR
    AJR Am J Roentgenol; 2008 Jan; 190(1):67-73. PubMed ID: 18094295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic resection for metastatic neuroendocrine carcinomas.
    Que FG; Nagorney DM; Batts KP; Linz LJ; Kvols LK
    Am J Surg; 1995 Jan; 169(1):36-42; discussion 42-3. PubMed ID: 7817996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.
    Ho AS; Picus J; Darcy MD; Tan B; Gould JE; Pilgram TK; Brown DB
    AJR Am J Roentgenol; 2007 May; 188(5):1201-7. PubMed ID: 17449759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hepatic metastasis of gastrointestinal carcinoid tumors.
    Landry CS; Scoggins CR; McMasters KM; Martin RC
    J Surg Oncol; 2008 Mar; 97(3):253-8. PubMed ID: 18264984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
    Strosberg JR; Choi J; Cantor AB; Kvols LK
    Cancer Control; 2006 Jan; 13(1):72-8. PubMed ID: 16508629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy.
    Bloomston M; Binitie O; Fraiji E; Murr M; Zervos E; Goldin S; Kudryk B; Zwiebel B; Black T; Fargher S; Rosemurgy AS
    Am Surg; 2002 Sep; 68(9):827-31. PubMed ID: 12356160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic neuroendocrine metastases: does intervention alter outcomes?
    Chamberlain RS; Canes D; Brown KT; Saltz L; Jarnagin W; Fong Y; Blumgart LH
    J Am Coll Surg; 2000 Apr; 190(4):432-45. PubMed ID: 10757381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases.
    Makary MS; Kapke J; Yildiz V; Pan X; Dowell JD
    J Vasc Interv Radiol; 2016 Sep; 27(9):1298-1304. PubMed ID: 27499157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
    Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
    BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.